Please login to the form below
insulin glargine
This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn
Sanofi has had a challenging few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma
Latest news
-
Sanofi said to be looking at options for $30bn consumer health unit
Sanofi has had a difficult few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma
-
Sanofi reveals positive phase 3 results for long-acting insulin Toujeo
Hopes new product can offset continuing decline in franchise. French-drugmaker Sanofi has revealed positive results for its long-acting insulin Toujeo (insulin glargine 300 units/mL), in a study which ... has compared it to Lantus (insulin glargine 100
-
Sanofi exits Zynquista alliance with Lexicon
The Sanofi/Lexicon partnered drug for type 1 diabetes was being co-developed as an add-on therapy to insulin injections to help improve blood sugar control. ... Zynquista was a key element in Sanofi’s plans to rebuild its diabetes franchise following
-
Pricing pressures peg back Lilly’s growth products
The only drug to beat analyst forecasts in the quarter was Basaglar – a biosimilar of Sanofi’s Lantus (insulin glargine) – which grew 51% to $251m.
-
Success for AZ, setback for Sanofi in type 1 diabetes
The decision is a blow to Sanofi’s hopes of rebuilding a diabetes franchise that has been hit the loss of patent protection for big-selling basal insulin Lantus (insulin glargine), ... Analysts have suggested that an oral drug approved as an insulin add
Sanofi said to be looking at options for $30bn consumer health unit
Sanofi reveals positive phase 3 results for long-acting insulin Toujeo
Pricing pressures peg back Lilly’s growth products
Success for AZ, setback for Sanofi in type 1 diabetes
More from news
Approximately 22 fully matching, plus 123 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
protection for Lantus (insulin glargine) – as well as cardiovascular disease research.
-
Deal Watch October 2018
agreement for the development and commercialisation of a follow‐on insulin glargine product to Sanofi’s Lantus.
-
Mylan sees the UK paving the way for an insulin game changer
As biosimilars surge into the insulin market, governments are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi
-
Going the distance
In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
-
Pharma deals during February 2013
Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option
20 for 2020 – Five pharma leaders to watch in 2020
Mylan sees the UK paving the way for an insulin game changer
Going the distance
Pharma deals during February 2013
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Sanofi promotes diabetes expert Paul Chew to chief medical officer
position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment
Sanofi promotes diabetes expert Paul Chew to chief medical officer
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
-
CEO, Head of Health, UK
-
Six figure salary
- Valneva COVID-19 vaccine more effective than AZ
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s COVID-19 antiviral under review in Europe by EMA
- AZ’s Imfinzi boosts survival in biliary tract cancer
- MAKING THE FIRST YEAR MATTER
- Merck receives first breast cancer approval in Europe for Keytruda
- Benefits of COVID-19 vaccine in younger children outweigh risks, says FDA
- Call for industry innovators to join working group
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Curb your conservatism: can pharma ditch its cautious approach to creativity in comms?
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Award-winning health agency 90TEN launches in the US
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
